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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic
inflammatory disease of unknown cause that can
affect the skin, joints, kidneys, lungs, nervous system,
serous membranes and/or other organs. Immunologic
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Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause that can affect any
organ, and is characterized by a wide range of autoantibodies. Several studies of large cohorts of SLE patients
have reported an increased prevalence of symptomatic subclinical cardiovascular disease (CVD). It is currently
believed that accelerated atherosclerosis in SLE results from a combination of numerous risk factors. In addition
to a high prevalence of traditional risk factors, inflammatory processes in SLE are considered to be important in
atherogenesis. Chronic activation or damage to the endothelium in SLE may trigger the inflammatory cascade
and thereby promote atherogenesis. Several forms of endothelial insult are being recognized in SLE, including
hypercholesterolemia, hyperhomocysteinemia, mechanical stress from hypertension, increased oxidative stress
and immunologic injury as a result of immune complex deposition. This review updates the modifiable risk
factors in SLE. The main focus is on the potential utility of these risk factors. The putative mechanisms of accentuated
risk as a result of underlying inflammation, and evidence for association with premature atherosclerosis are
discussed. Strategies that may be useful in preventing the progression of atheroma in this population include close
monitoring and aggressive treatment of the traditional risk factors as in patients with high risk of CVD. The role
of antioxidants and immunomodulators are also explored. [Hong Kong J Nephrol 2006;8(2):48–54]
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abnormalities, especially the production of a wide range
of antinuclear antibodies, are another prominent feature
of the disease [1].
With improved long-term survival, longitudinal
cohort studies determined prognostic factors and
disease outcome in SLE patients. A bimodal mortality
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distribution in SLE patients was first reported in the
late 1970s [2], in a 5-year prospective study of 81
patients, of whom 11 died. The six early deaths resulted
from active lupus nephritis or sepsis occurring in the
first year of diagnosis. The five late deaths, which
occurred after approximately 9 years, were attributed
to myocardial infarction.
Several studies of large cohorts of patients from
North America with SLE reported the prevalence of
symptomatic cardiovascular disease (CVD), presenting
as angina pectoris, myocardial infarction or sudden
death, as 6.6–8.9% [3–5]. In addition to cohort studies
by tertiary centers, a community-based study
demonstrated that young women with SLE were 2.3
times more likely to be hospitalized because of
myocardial infarction (odds ratio [OR], 2.3) [6]. The
incidence rates of myocardial infarction in women
with SLE in the 35–44 years old age group were more
than 50 times those of women of similar age in the
Framingham Offspring Study [5]. All these studies
provided evidence that women with SLE are at
increased risk of premature atherosclerosis, leading to
symptomatic CVD, compared with the general
population.
In view of the heavy burden of clinical CVD,
together with advances in investigational tools for early
detection of subclinical atherosclerosis, investigators
were interested in assessing the true prevalence of
subclinical atherosclerosis and to intervene early before
patients develop clinical CVD. Noninvasive imaging
techniques such as carotid ultrasound were commonly
used to look for the presence of carotid plaques. The
prevalence of carotid plaques in women with SLE
without clinical CVD ranged from 17% (defined as at
least one focal plaque with maximum intima–media
thickness > 0.9 mm) [7] to 32% (intima–media
thickness >1.3 mm) [8].
Myocardial perfusion scintigraphy has also been
used to estimate the prevalence of myocardial perfusion
defects in SLE without history of CVD. Two studies
were done using single photon emission computed
tomography (CT) with technetium-99-m, with or
without thallium-201, and demonstrated that perfusion
defects were present in 35% [9] and 28% [10],
respectively.
Recently, electron-beam CT was used to screen for
the presence of coronary artery calcification. It is useful
for predicting CVD-related death and non-fatal
myocardial infarction and the need for revascularization
procedures even in asymptomatic individuals [11]. In
SLE patients with no history of CVD, the prevalence
of coronary artery calcification was higher (30.8%) than
in controls (8.7%) (p = 0.002) [12].
In summary, these studies suggest that the overall
prevalence of subclinical atherosclerosis in SLE patients
ranges from 17% to 35%.
WHY ARE SLE PATIENTS AT INCREASED RISK OF
PREMATURE ATHEROSCLEROSIS?
It is currently believed that atherosclerosis in the general
population results from a combination of numerous
risk factors. In addition to traditional risk factors,
inflammatory processes are now considered to be
important in atherogenesis [13].
The healthy endothelium is involved in the
maintenance of short-term blood pressure and flow
homeostasis and prevention of unwarranted clotting.
The endothelium responds to increased blood flow or
pressure, activating protein kinase B, which stimulates
the production of the vasodilators nitric oxide (NO) and
prostaglandin I2 [14,15]. The enzymes associated with
their production, NO synthase and phospholipase A2,
can also be activated by increased intracellular calcium
levels triggered by the coagulation cascade, in which
NO and prostaglandin I2 have an inhibitory role. The
funct ioning endothel ium also produces the
vasoconstrictors thromboxane and endothelin-1,
excessive levels of which may be associated with
hypertension [16]. Loss of the functional integrity of
the endothelial cell lining following injury triggers a
cascade involving the coagulation, kinin, complement,
and fibrinolytic systems, which normally leads to repair
of the injured site with restoration of normal function.
Inflammatory processes probably contribute to
atherogenesis in SLE, a disease characterized by
chronic inflammation. Chronic activation or damage
to the endothelium may lead to imbalance in these
interacting systems and thereby promote atherogenesis.
Several forms of endothelial insult are recognized:
chemical stress such as from smoking, hyper-
cholesterolemia or hyperhomocysteinemia; mechan-
ical stress from hypertension; and immunologic injury
(Figure 1). Many of these factors have been reported to
be present in patients with SLE [3,17,18]. In essence,
it is believed that the interaction between traditional
risk factors, inflammation-induced and antibody-
mediated vascular injury or thrombosis, and immune
dysregulation from the underlying disease, all play
important roles in endothelial dysfunction that
accelerate the atherosclerotic process in SLE, as
depicted in Figure 2.
THERAPEUTIC OPPORTUNITIES
It is important that physicians caring for SLE patients
are aware of the risk of CVD complications associated
with this disorder since atheromatous disease is
otherwise unusual in premenopausal women, except
for diabetics. Modifiable risk factors should be
monitored routinely if possible (Table). Once identified,
the risk factors should be treated aggressively by
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Figure 2. Summary of the interaction
between different risk factors leading to
endothelial damage in systemic lupus
erythematosus (SLE). Risk factors that
can cause direct endothelial damage are
shaded. APLS = antiphospholipid
syndrome; HT = hypertension; LDL =
low-density lipoprotein; oxLDL = oxi-
dized low-density lipoprotein; 2GP1 =
2 glycoprotein 1; EDNO = endothelial
derived nitric oxide.
Figure 1. Mechanisms and consequences
of endothelial damage in patients with
systemic lupus erythematosus (SLE).
Table. Potential treatment for the modifiable risk factors for premature atherosclerosis in systemic lupus erythematosus
Risk factor Treatment
Diabetes mellitus Insulin or oral hypoglycemic agents
Hypertension Antihypertensives
Dyslipidemia Statins, antimalarial agents
Smoking Smoking cessation
Obesity Diet and exercise
Prothrombotic state Antimalarial agents
Insulin resistance Antimalarial agents
Low antioxidant levels Antioxidant supplements
Hyperhomocysteinemia Folic acid supplement
Fibrinogen Smoking cessation, exercise, alcohol intake, estrogen, fibrates(?)
Lipoprotein(a) Apheresis, estrogens, niacin, gemfibrozil, 3-fatty acids
Cytokines and inflammatory markers Immunomodulating agents(?)
Microalbuminuria Angiotensin-converting enzyme inhibitor
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means of patient education and lifestyle modification
in terms of diet, exercise, smoking cessation and
weight reduction. Other potential treatments for the
modifiable risk factors are discussed in the following
paragraphs.
Antimalarial agents
Hydroxychloroquine is the most commonly prescribed
antimalarial medication for lupus and is useful in the
management of mucocutaneous manifestations,
arthritis and mild constitutional symptoms [19].
Hydroxychloroquine has many additional benefits in
lupus patients. It has been reported to lower total and
low-density lipoprotein (LDL)-cholesterol and
triglyceride (TG) levels in patients with rheumatoid
arthritis or SLE [20]. A cholesterol-lowering effect was
also identified in a longitudinal cohort study of 264
SLE patients, with a mean follow-up time of 3 years: a
dose of prednisone 10 mg was associated with an
increase in serum cholesterol levels of 75 mg/L, which
was offset by the use of hydroxychloroquine [21]. Use
of hydroxychloroquine has also been shown to be
associated with lower pulse wave velocity in
premenopausal women, suggesting a potential
protective effect against future development of major
vascular disease [22].
The effects of antimalarials on fasting lipid profiles
in SLE are scanty. We did a study on the relative effect
of antimalarial agents on fasting lipid fractions in
patients with active SLE [23]. A total of 123 patients
were studied; 73.2% were taking prednisone (mean ±
SD dose of 10.9 ± 9.2 mg/day), 48.0% were taking
antimalarial agents and 30.8% were taking both. Total
cholesterol, very-low-density lipoprotein (VLDL)-
cholesterol, and LDL-cholesterol levels were
significantly lower in patients taking antimalarial
agents, particularly in those patients taking concomitant
prednisone.
The lipid-lowering effect of antimalarial agents in
lupus patients who are not on prednisone, and the effects
on other lipoproteins, e.g. lipoprotein(a) levels, remain
controversial [20,21,24,25]. Therefore, in another study,
we investigated the effects of hydroxychloroquine in
65 SLE patients who were either on a low dose of
prednisone or not on prednisone, and demonstrated that
hydroxychloroquine had no significant effect on the
serum lipid profile of these lupus patients with mild or
inactive disease [26].
Hydroxychloroquine, a platelet inhibitor, has also
been reported to reduce thromboembolic events in
patients with SLE and antiphospholipid syndrome
[27–29]. Antimalarials have been reported to
significantly improve insulin resistance and glycemic
control in SLE patients, with and without type 2
diabetes, which should also contribute to a reduction
in cardiovascular risk [30].
Statins
As elevated cholesterol levels are a strong risk factor
for future renovascular, cerebrovascular and
cardiovascular events, lipid-lowering therapy is
important. In addition to antimalarials, the 3-hydroxy-
3-methylglutaryl-coenzyme A reductase inhibitors, or
statins, are not only useful in treating elevated
cholesterol levels, but have also been shown to reduce
cardiovascular events and total mortality in high-risk
groups [31]. The statins may also be particularly useful
for treating patients with SLE, as they appear to have
additional antithrombotic and anti-inflammatory effects
[32,33].
Atorvastatin significantly reduced arterial stiffness
in patients with rheumatoid arthritis. The greatest
improvements were seen in patients with more active
disease, suggesting that, in addition to the beneficial
effects of cholesterol reduction, immune modulation
may contribute to the cardioprotective effect of statins
[34]. However, lupus-like syndrome or severe acute
hepatitis have been documented after taking statins
[35–38]. An ongoing multicenter, randomized,
controlled trial, Atherosclerosis Prevention in Pediatric
Lupus Erythematosus (APPLE), testing the efficacy of
statins in preventing premature atherosclerosis in
children and adolescents with SLE will guide future
therapeutic intervention [39].
Antihypertensives
Aggressive treatment of hypertension is important in
reducing vascular events, particularly in patients with
renal complications. In patients with high-risk renal
disease, angiotensin-converting enzyme inhibitors
(ACEIs), calcium channel blockers and -blockers are
all beneficial [40]. ACEIs may have benefits in
addition to their blood pressure-lowering efficacy in
the treatment of diabetic renal disease [41]. Reducing
the level of microalbuminuria in diabetics is
renoprotective and cardiovasculo-protective [42].
However, direct comparisons between ACEIs and
other antihypertensives are not available in patients
with SLE, and the merits of reducing the level of
microalbuminuria in non-diabetic patients are
uncertain.
Folate supplementation
A recent meta-analysis reported that in prospective
studies, the increase in the risk of cardiovascular events
due to elevated homocysteine levels is modest [43].
After adjustment for conventional cardiovascular risk
factors, a 25% lower homocysteine level was associated
with an 11% lower CVD risk and a 19% lower stroke
risk. Folate supplementation to reduce homocysteine
levels may be considered [44], but homocysteine levels
are not routinely monitored. Folic acid may have
benefic ia l  effects  independent  of  lowering
L.S. Tam, et al
52 Hong Kong J Nephrol • October 2006 • Vol 8 • No 2
homocysteine levels [45,46], including antioxidant
properties and upregulation of endothelial NO synthase
[45]. Unfortunately, two recent randomized trials on
folate supplementation did not show any beneficial
effect on secondary prevention of CVD despite the
lowering of homocysteine levels [47,48]. Therefore, the
use of folate supplements cannot be recommended at
this moment.
Antioxidant supplementation
The majority of the large-scale prospective studies on
antioxidant vitamins, including vitamins C and E or a
combination, failed to demonstrate any benefit in
preventing CVD events [49], probably because the
target  populat ions  a l ready had es tabl ished
atherosclerotic disease. Since oxidative stress is
involved in the early atherogenic process, antioxidant
vitamins may be useful in preventing progression. Data
suggest that supplementation with vitamins C or E alone
can improve endothelial dysfunction in some conditions
associated with increased oxidative stress [50–52], but
not in other conditions [53–56]. We evaluated the effects
of long-term antioxidant vitamins on markers of
oxidative stress and antioxidant defence and endothelial
function in 39 SLE patients [57]. Patients were
randomized to receive either placebo or vitamins
(500 mg vitamin C and 800 IU vitamin E daily) for 12
weeks. After treatment, plasma ascorbic acid and
-tocopherol concentrations were significantly
increased only in the vitamin-treated group, associated
with a significant decrease in plasma malondialdehyde
level. Other oxidative stress markers and antioxidant
levels remained unchanged in both groups. Flow-
mediated dilatation, von Willebrand factor and
plasminogen activator inhibitor-1 levels remained
unchanged in both groups. The results showed that
antioxidant supplementation only had a modest effect
on lipid peroxidation, but did not affect other oxidative
stress markers or endothelial function in patients with
SLE, probably because the underlying inflammatory
process was not suppressed.
Anti-inflammatory agents
As atherosclerosis is an inflammatory disease,
corticosteroids could be expected to have an
antiatherogenic effect, a possibility supported by one
experimental study using an animal model [58]. In
contrast, corticosteroids have well-known metabolic
effects that could, in theory, be proatherogenic [21],
and advanced atherosclerosis has been described in
patients treated with steroids [59]. It should be noted
that treatment is implemented due to higher
inflammatory reactivity and a history of steroid
treatment could simply reflect a higher inflammatory
activity, which, per se, could be an important risk factor
[60,61]. Relatively little is known about the role of other
treatments in SLE in relation to CVD. One study did
not find any association between other medications
commonly used in SLE and CVD [60]. However,
Roman et al [62] described a negative association
between immunosuppression and atherosclerosis.
Other potential agents
The lack of standardized assays has limited the use of
conditional risk factors such as fibrinogen and
lipoprotein(a). A drug that specifically lowers
fibrinogen levels is not yet available. Nevertheless,
smoking cessation, exercise and reduced alcohol intake
can lower fibrinogen levels [63]. Estrogen and fibrate
lower both fibrinogen and lipoprotein(a) levels [64–67].
Niacin and 3-fatty acids have been reported to lower
lipoprotein(a) levels [68,69]. No outcome studies are
available to show that lowering of these risk factors
leads to a reduction in vascular events.
CONCLUSION
The importance of conventional risk factors in
increasing the burden of atherosclerosis in the lupus
population is well documented. Efforts need to be
intensified to aggressively treat these and other
modifiable risk factors or to prevent their onset as
summarized in the Table. Well-conducted clinical trials
are now needed to advance beyond these initial
recommendations.
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